Intra‐arterial chemotherapy for retinoblastoma: Centralization of care is essential

Abstract

Retinoblastoma is highly curable in high-income settings, so most current treatments aim to increase the ocular preservation rate retaining vision, while reducing the treatment burden, especially in children with germline mutations of the RB1 gene who are at higher risk of treatment-induced secondary malignancies. In the mid-1990s, the use of systemic chemoreduction of intra-ocular tumors allowed for a decreased use of external-beam radiotherapy which has been associated with radiation-induced neoplasms in children with the RB1 gene germline mutation...